Form 4: Kymera Therapeutics Director Exercises Options and Sells Shares Under Pre-Arranged Plan

Kymera Therapeutics, Inc. Director Jeffrey W. Albers executed a pre-arranged transaction, exercising stock options and subsequently selling the acquired common stock.

Summary

• Jeffrey W. Albers, a Director at Kymera Therapeutics, Inc. (KYMR), reported changes in his beneficial ownership of company securities.
• On June 3, 2025, Mr. Albers acquired 6,349 shares of common stock by exercising stock options at a price of $10.34 per share.
• Immediately following the acquisition, Mr. Albers disposed of all 6,349 shares of common stock at a price of $49.00 per share.
• Both transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Albers on September 20, 2024.
• After these transactions, Mr. Albers directly holds 0 shares of common stock.
• Mr. Albers continues to hold 5,000 stock options (right to buy) with an exercise price of $10.34, which are fully vested and exercisable, and expire on September 3, 2030.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized by the insider from the option exercise and sale is a positive for the individual, but not directly for the company's operational performance.

Positives

• The sale price of $49.00 per share is significantly higher than the exercise price of $10.34 per share, indicating a substantial profit for the insider on the exercised options.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests a pre-scheduled and non-discretionary sale, often mitigating concerns about opportunistic insider selling.

Negatives

• The disposition of 6,349 shares by a director, even under a 10b5-1 plan, represents an insider selling activity, which can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

This document, a Form 4, reports past transactions and does not provide forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction (option exercise and sale) and does not provide information relevant to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: May note the director's decision to sell shares, although the pre-arranged nature of the transaction under a 10b5-1 plan typically reduces its perceived negative impact compared to an unannounced, discretionary sale.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Jeffrey W. Albers, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Beneficial Ownership